Atypical Presentation of an Ovarian Yolk Sac Tumor in an 80-Year-Old Woman: A Case Report and Review of the Literature.

Introduction: Ovarian yolk sac tumors after the menopause are very rare.

Case Presentation: We report an atypical case of yolk sac tumor in an octogenarian woman, who presented to the hospital with anasarca, ascites, toxic syndrome, and an abdominal mass. Serum alpha-fetoprotein (AFP) levels were highly increased (246,720 ng/mL), and malignant cells with positive AFP immunohistochemical expression were detected in a diagnostic paracentesis.

Ovarian Cancer Retrospective European (O'CaRE) study: first-line outcomes by number of risk factors for progression.

The Ovarian Cancer Retrospective European (O'CaRE) study assessed the cumulative impact of high-risk factors on progression-free survival (PFS) and overall survival (OS) following first-line treatment in patients diagnosed with advanced ovarian cancer. Medical records were collected from five European countries (2014 and 2015). Patients were grouped by number of high-risk factors: stage IV diagnosis, no known , interval debulking surgery or no surgery, or visible residual disease.

Multicenter Real-World Data of Subsequent Chemotherapy after Progression to PARP Inhibitors in a Maintenance Relapse Setting.

Background: Despite impressive progression-free survival (PFS) results from PARP inhibitors (PARPi) in ovarian cancer, concerns about their effect on post-progression treatment outcomes have recently arisen, particularly when administered in the relapsed setting. Overlapping mechanisms of resistance between PARPi and platinum have been described, and optimal therapies upon progression to PARPi are unknown. We communicate real-world data (RWD) on outcomes of subsequent chemotherapy upon progression to PARPi used as maintenance in ovarian cancer relapses, particularly focusing on platinum rechallenge, according to BRCA status.